Patient ID | Dose level | Disease at study entry | Prior therapy | Response to prior systemic treatment | Cycles of lutathera, n | Best response to study treatment |
1 | 1 | ES-SCLC | Carboplatin/etoposide/RT | PD | 2 | PD |
2 | 1 | ES-SCLC | Carboplatin/etoposide | SD | 2 | PR |
3 | 1 | ES-SCLC | Carboplatin/etoposide | PD | 1 | PD |
4 | 2 | Atypical carcinoid |
| NA | 3 | SD |
5 | 2 | ES-SCLC |
| SD | 4 | NE* |
6 | 2 | ES-SCLC |
| PD | 1 | PD |
7 | 2 | Atypical carcinoid | Carboplatin/etoposide/lanreotide | PD | 3 | SD |
8 | 2 | High-grade neuroendocrine carcinoma |
| PD | 1 | PD |
9 | 2 | ES-SCLC | Carboplatin and etoposide followed by thoracic RT | PR | 2 | NE* |
*Not evaluable due to no measurable disease.
ES-SCLC, extensive-stage small-cell lung cancer; NA, not available; NE, not evaluable; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease.